A novel small‐molecular inhibitor AMG510 targeting to a KRAS mutation G12C presented valid anti‐cancer ability for patients with non–small‐cell lung cancer in the phase I clinical trial16 and may be of help for the 100% KRAS mutated late‐stage pancreatic body/tail cancers. Here, KRAS is linked to cancer.